| Ytd | -28.57% | |
| 1y | -28.81% |
| Open | 6.35 | Prev Close | 6.43 | Low | 6.29 | High | 6.38 | Mkt Cap | 597.39M |
| Vol | 11.55K | Avg Vol | 75.63K | EPS | -2.10 | P/E | N/A | Forward P/E | -7.21 |
| Beta | 1.02 | Short Ratio | 1.22 | Inst. Own | 1.16% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 5.53 | 200-d Avg | 7.44 | 1yr Est | 15.85 |
VALN News
Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector.
Stock futures mixed, Nasdaq 100 down 100 points. Applied Optoelectronics falls after announcing $600
Valneva (VALN) is transitioning from a low-margin vaccine manufacturer to a high-margin royalty and
Valneva SE (NASDAQ:VALN) stock is surging on Friday after the company and its partner Pfizer Inc. (N
Valneva (VALN) stock surges after EMA validates MAA for Lyme disease vaccine candidate developed wit
Dow falls 0.26% while Nasdaq drops 0.51%. Energy shares rise 1.3%, tech stocks fall 0.6%. US retail
U.S. stocks up, Dow Jones 0.1% higher. HeartFlow (HTFL) shares rise 26.5% on better-than-expected ea
Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market
Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results
NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euro
NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euro
Valneva SE (VALN) Q2 2026 Earnings Call Transcript
Valneva NASDAQ: VALN reported lower first-half revenue and wider losses for 2026, while maintaining
Valneva (NASDAQ:VALN) affirms FY2026 sales outlook from $169.795 million-$187.360 million to $169.79
Total product sales of €64.0 millionIn-line with expectations; full-year guidance of €135 -150 milli
Lyon (France), August 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine
Ventes totales de produits de 64,0 millions d'euros o En ligne avec les attentes; confirmation de la
Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's
Lyon (France), July 22, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine c
Valneva SE (VALN) Shareholder/Analyst Call Prepared Remarks Transcript
Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 –
Lyon (France), June 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine co
Lyon (France), May 28, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine co
Lyon (France), le 28 mai 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée
Valneva NASDAQ: VALN reported lower first-quarter revenue and a wider loss for 2026, while managemen
Valneva SE (VALN) Q1 2026 Earnings Call Transcript
Valneva (NASDAQ:VALN) lowers FY2026 sales outlook from $180.443 million-$197.906 million to $169.795
Valneva (NASDAQ:VALN) reported quarterly losses of $(0.42) per share which missed the analyst consen
Lyon (France), May 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine co
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors o
Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon
US stock futures lower, Dow futures down 200 points. Norwegian Cruise Line shares fall after Q1 resu
Dow futures up 250 points. Sonoco Products Co (SON) shares down 5.7% in pre-market after reporting l
Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial
Dow up 2.45%, Nasdaq up 2.46%, S&P 500 up 2.19%. Consumer discretionary shares up 3.6%, energy s
Valneva stock drops after Phase 3 Lyme vaccine misses primary endpoint; secondary data shows efficac
Dow Jones rises over 800 points on Monday as U.S. stocks trade higher. NASDAQ and S&P 500 also s
Dow futures up 1000 points. Valneva stock falls in pre-market. Pfizer and Valneva announce Phase 3 r
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease
Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against seri
Dow futures up 200 points, ClearPoint Neuro (CLPT) stock falls after wider-than-expected quarterly l
Valneva (NASDAQ:VALN) affirms FY2026 sales outlook from $180.443 million-$197.906 million to $180.44
Valneva (NASDAQ:VALN) reported quarterly losses of $(0.68) per share which missed the analyst consen